Biomarkers for Hepatobiliary Cancers

被引：154

作者：

Nault, Jean-Charles ^{[1
,2
,3
]}

Villanueva, Augusto ^{[4
,5
]}

机构：

[1] Univ Paris 13, Funct Genom Solid Tumors Lab, Ctr Rech Cordeliers, Sorbonne Univ,Inserm,USPC,Univ Paris Descartes,Un, Paris, France

[2] Hop Univ Paris Seine St Denis, AP HP, Hop Jean Verdier, Liver Unit, Bondy, France

[3] Univ Paris 13, Unite Format & Rech Sante Med & Biol Humaine, Paris, France

[4] Icahn Sch Med Mt Sinai, Liver Canc Program, Tisch Canc Inst, Div Liver Dis,Dept Med, 1425 Madison Ave,Box 1123,Room 11-70E, New York, NY 10029 USA

[5] Icahn Sch Med Mt Sinai, Dept Med, Div Hematol & Med Oncol, New York, NY 10029 USA

来源：

HEPATOLOGY | 2021年 / 73卷

关键词：

ADVANCED HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; EXTRACELLULAR VESICLES; THERAPEUTIC TARGETS; DOUBLE-BLIND; PHASE-II; CHOLANGIOCARCINOMA; PROGNOSIS; MUTATIONS; SUBTYPES;

D O I：

10.1002/hep.31175

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The clinical management of primary liver cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) has significantly changed in the last 3 years. The introduction of systemic therapies, including immune-based therapies and biomarker-driven therapies, has significantly improved survival, particularly in patients at advanced stages of disease. Survival is still poor, and projections from the World Health Organization underscore the need to improve outcomes in these patients. Biomarkers have emerged as powerful tools for the diagnosis, prognosis, and prediction of treatment responses to improve patient stratification and maximize clinical benefits. Recent advances in understanding the molecular alterations of HCC have not yet translated into biomarkers. Some reasons for the lack of progress are the absence of druggable mutations in the majority of liver cancers and the significant heterogeneity of the disease. In contrast, several therapeutic targets have been identified in CCA, and biomarker-driven therapies are currently under evaluation in phase 2/3 clinical trials. Here, we summarize the status on biomarker development for HCC and CCA.

引用

页码：115 / 127

页数：13

共 98 条

[21] β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma [J].

de Galarreta, Marina Ruiz ;

Bresnahan, Erin ;

Molina-Sanchez, Pedro ;

Lindblad, Katherine E. ;

Maier, Barbara ;

Sia, Daniela ;

Puigvehi, Marc ;

Miguela, Vernica ;

Casanova-Acebes, Maria ;

Dhainaut, Maxime ;

Villacorta-Martin, Carlos ;

Singhi, Aatur D. ;

Moghe, Akshata ;

von Felden, Johann ;

Grinspan, Lauren Tal ;

Wang, Shuang ;

Kamphorst, Alice O. ;

Monga, Satdarshan P. ;

Brown, Brian D. ;

Villanueva, Augusto ;

Llovet, Josep M. ;

Merad, Miriam ;

Lujambio, Amaia .

CANCER DISCOVERY, 2019, 9 (08) :1124-1141

[22] Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy [J].

Dudley, Jonathan C. ;

Zheng, Zongli ;

McDonald, Thomas ;

Le, Long P. ;

Dias-Santagata, Dora ;

Borger, Darrell ;

Batten, Julie ;

Vernovsky, Kathy ;

Sweeney, Brenda ;

Arpin, Ronald N. ;

Brugge, William R. ;

Forcione, David G. ;

Pitman, Martha B. ;

Iafrate, A. John .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (01) :124-130

[23] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].

El-Khoueiry, Anthony B. ;

Sangro, Bruno ;

Yau, Thomas ;

Crocenzi, Todd S. ;

Kudo, Masatoshi ;

Hsu, Chiun ;

Kim, Tae-You ;

Choo, Su-Pin ;

Trojan, Jorg ;

Welling, Theodore H., III ;

Meyer, Tim ;

Kang, Yoon-Koo ;

Yeo, Winnie ;

Chopra, Akhil ;

Anderson, Jeffrey ;

dela Cruz, Christine ;

Lang, Lixin ;

Neely, Jaclyn ;

Tang, Hao ;

Dastani, Homa B. ;

Melero, Ignacio .

LANCET, 2017, 389 (10088) :2492-2502

[24] EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (vol 69, pg 182, 2018) [J].

Galle, Peter R. ;

Forner, Alejandro ;

Llovet, Josep M. ;

Mazzaferro, Vincenzo ;

Piscaglia, Fabio ;

Raoul, Jean-Luc ;

Schirmacher, Peter ;

Vilgrain, Valerie .

JOURNAL OF HEPATOLOGY, 2019, 70 (04) :817-817

[25] Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J].

Finn, Richard S. ;

Ryoo, Baek-Yeol ;

Merle, Philippe ;

Kudo, Masatoshi ;

Bouattour, Mohamed ;

Lim, Ho Yeong ;

Breder, Valeriy ;

Edeline, Julien ;

Chao, Yee ;

Ogasawara, Sadahisa ;

Yau, Thomas ;

Garrido, Marcelo ;

Chan, Stephen L. ;

Knox, Jennifer ;

Daniele, Bruno ;

Ebbinghaus, Scot W. ;

Chen, Erluo ;

Siegel, Abby B. ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) :193-+

[26]

Finn RS., 2018, Ann Oncol, V29, pviii17, DOI DOI 10.1093/ANNONC/MDY269.057

[27] An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples [J].

Fritcher, Emily G. Barr ;

Voss, Jesse S. ;

Brankley, Shannon M. ;

Campion, Michael B. ;

Jenkins, Sarah M. ;

Keeney, Matthew E. ;

Henry, Michael R. ;

Kerr, Sarah M. ;

Chaiteerakij, Roongruedee ;

Pestova, Ekaterina V. ;

Clayton, Amy C. ;

Zhang, Jun ;

Roberts, Lewis R. ;

Gores, Gregory J. ;

Halling, Kevin C. ;

Kipp, Benjamin R. .

GASTROENTEROLOGY, 2015, 149 (07) :1813-+

[28] Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma [J].

Goeppert, Benjamin ;

Toth, Reka ;

Singer, Stephan ;

Albrecht, Thomas ;

Lipka, Daniel B. ;

Lutsik, Pavlo ;

Brocks, David ;

Baehr, Marion ;

Muecke, Oliver ;

Assenov, Yassen ;

Gu, Lei ;

Endris, Volker ;

Stenzinger, Albrecht ;

Mehrabi, Arianeb ;

Schirmacher, Peter ;

Plass, Christoph ;

Weichcnhan, Dieter ;

Roessler, Stephanie .

HEPATOLOGY, 2019, 69 (05) :2091-2106

[29] TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma [J].

Goyal, Lipika ;

Shi, Lei ;

Liu, Leah Y. ;

de la Cruz, Ferran Fece ;

Lennerz, Jochen K. ;

Raghavan, Srivatsan ;

Leschiner, Ignaty ;

Elagina, Liudmila ;

Siravegna, Giulia ;

Ng, Raymond W. S. ;

Phuong Vu ;

Patra, Krushna C. ;

Saha, Supriya K. ;

Uppot, Raul N. ;

Arellano, Ron ;

Reyes, Stephanie ;

Sagara, Takeshi ;

Otsuki, Sachie ;

Nadres, Brandon ;

Shahzade, Heather A. ;

DeyGuha, Ipsita ;

Fetter, Isobel J. ;

Baiev, Islam ;

Van Seventer, Emily E. ;

Murphy, Janet E. ;

Ferrone, Cristina R. ;

Tanabe, Kenneth K. ;

Deshpande, Vikram ;

Harding, James J. ;

Yaeger, Rona ;

Kelley, Robin K. ;

Bardelli, Alberto ;

Iafrate, A. John ;

Hahn, William C. ;

Benes, Cyril H. ;

Ting, David T. ;

Hirai, Hiroshi ;

Getz, Gad ;

Juric, Dejan ;

Zhu, Andrew X. ;

Corcoran, Ryan B. ;

Bardeesy, Nabeel .

CANCER DISCOVERY, 2019, 9 (08) :1064-1079

[30] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma [J].

Goyal, Lipika ;

Saha, Supriya K. ;

Liu, Leah Y. ;

Siravegna, Giulia ;

Leshchiner, Ignaty ;

Ahronian, Leanne G. ;

Lennerz, Jochen K. ;

Vu, Phuong ;

Deshpande, Vikram ;

Kambadakone, Avinash ;

Mussolin, Benedetta ;

Reyes, Stephanie ;

Henderson, Laura ;

Sun, Jiaoyuan Elisabeth ;

Van Seventer, Emily E. ;

Gurski, Joseph M., Jr. ;

Baltschukat, Sabrina ;

Schacher-Engstler, Barbara ;

Barys, Louise ;

Stamm, Christelle ;

Furet, Pascal ;

Ryan, David P. ;

Stone, James R. ;

Iafrate, A. John ;

Getz, Gad ;

Porta, Diana Graus ;

Tiedt, Ralph ;

Bardelli, Alberto ;

Juric, Dejan ;

Corcoran, Ryan B. ;

Bardeesy, Nabeel ;

Zhu, Andrew X. .

CANCER DISCOVERY, 2017, 7 (03) :252-263

← 1 2 3 4 5 6 7 8 9 10 →